ORIC Pharmaceuticals (ORIC) – Analysts’ Weekly Ratings Updates

ORIC Pharmaceuticals (NASDAQ: ORIC) recently received a number of ratings updates from brokerages and research firms:

• 9/18/2024 – ORIC Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
• 9/10/2024 – ORIC Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
• 9/9/2024 – ORIC Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 9/6/2024 – ORIC Pharmaceuticals is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $20.00 price target on the stock.
• 8/14/2024 – ORIC Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
• 8/13/2024 – ORIC Pharmaceuticals had its price target lowered by analysts at Oppenheimer Holdings Inc. from $17.00 to $15.00. They now have an “outperform” rating on the stock.
• 8/12/2024 – ORIC Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.

ORIC Pharmaceuticals Stock Performance

ORIC Pharmaceuticals stock traded up $0.01 during mid-day trading on Friday, reaching $11.17. The company’s stock had a trading volume of 318,882 shares, compared to its average volume of 530,005. The firm’s fifty day moving average price is $10.04 and its two-hundred day moving average price is $10.06. The company has a market capitalization of $753.10 million, a P/E ratio of -6.21 and a beta of 1.12. ORIC Pharmaceuticals, Inc. has a 12-month low of $5.27 and a 12-month high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). On average, research analysts predict that ORIC Pharmaceuticals, Inc. will post -1.78 EPS for the current fiscal year.

Hedge Funds Weigh In On ORIC Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ORIC Pharmaceuticals by 162.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock valued at $36,000 after purchasing an additional 3,188 shares in the last quarter. Quest Partners LLC raised its stake in ORIC Pharmaceuticals by 253.2% in the second quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock worth $73,000 after buying an additional 7,440 shares in the last quarter. XTX Topco Ltd purchased a new stake in ORIC Pharmaceuticals during the second quarter worth $153,000. Cornercap Investment Counsel Inc. bought a new stake in ORIC Pharmaceuticals during the 2nd quarter valued at $154,000. Finally, Profund Advisors LLC increased its holdings in shares of ORIC Pharmaceuticals by 23.6% in the 2nd quarter. Profund Advisors LLC now owns 21,861 shares of the company’s stock valued at $155,000 after acquiring an additional 4,175 shares during the period. Institutional investors own 95.05% of the company’s stock.

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.